Fasoracetam: The Racetam Being Studied for ADHD

Fasoracetam: The Racetam Being Studied for ADHD

Most racetams promise sharper focus and better memory with thin evidence behind them. Fasoracetam is the rare exception that earned a real clinical trial in real patients. It reached children with ADHD, in a hospital, with a specific genetic test deciding who got in.

That detail matters more than the focus-forum hype around it. Fasoracetam was not studied as a general study aid. It was studied as a precision drug for a small, genetically defined slice of people with ADHD.

Here is what the science actually shows, what it does not, and why you cannot buy a legitimate version of it for your morning routine.

Key Takeaways

• Fasoracetam is an investigational drug, not an approved medication or a legal supplement ingredient.
• It works mainly through metabotropic glutamate receptors (mGluRs), not the AMPA pathway most racetams target.
• The main ADHD evidence comes from a single trial in adolescents who carried specific mGluR gene mutations.
• Those mutations appear in roughly 10% of ADHD cases, so most people would likely see no benefit.
• It sits in a legal gray zone in the United States and is not sold as an approved product.

What Is Fasoracetam?

Fasoracetam is a synthetic compound in the racetam family, originally coded NFC-1 and NS-105 in research settings. Japanese scientists developed it in the late 1980s, first chasing treatments for memory loss tied to aging and poor blood flow in the brain. That early program never produced an approved drug, and the compound sat mostly idle for years.

It came back through genetics. Researchers at the Children's Hospital of Philadelphia, led by Hakon Hakonarson, revived fasoracetam as a candidate for ADHD and other neuropsychiatric conditions. His work founded a company that became part of Aevi Genomic Medicine, and the compound moved into human trials under the name NFC-1.

So the modern story of fasoracetam is not a nootropic story. It is a drug-development story built around a single biological target.

How Fasoracetam Works: The mGluR Mechanism

Fasoracetam acts on metabotropic glutamate receptors, a system that fine-tunes how brain cells use glutamate, the brain's main excitatory signal. This is the core of the fasoracetam mGluR mechanism, and it separates the compound from older racetams.

Most racetams nudge the AMPA receptor and cholinergic system. Fasoracetam instead behaves as a partial agonist at the mGluR5 receptor and shows affinity for GABA-B receptors. It also appears to increase the number of GABA-B receptors over time, which researchers link to its calming and pro-cognitive effects in animal models.

There is a second layer worth understanding. Fasoracetam is reported to enhance group II metabotropic glutamate receptor signaling, which tempers presynaptic glutamate release, and to raise acetylcholine release in the cortex. In plain terms, it tries to rebalance an overactive or poorly regulated glutamate system rather than simply flooding the brain with stimulation.

That mechanism is the whole reason the ADHD research targeted a specific genetic group.

Fasoracetam and ADHD: What the Research Actually Found

The strongest fasoracetam ADHD evidence comes from one trial in adolescents who carried mutations in the mGluR gene network, not the general ADHD population. This is the single most important fact in the entire fasoracetam story.

The published fasoracetam study ran in adolescents aged 12 to 17 who had ADHD and disruptive mutations in genes tied to mGluR signaling. The trial used single-dose pharmacokinetic profiling from 50 to 800 mg, then advanced patients up to 400 mg twice daily over several weeks, and reported marked improvement on the Clinical Global Impressions scale. The results appeared in Nature Communications in 2018.

A separate write-up of the same program describes the design clearly. The study examined safety, pharmacokinetics, and response to fasoracetam (NFC-1) in 30 teenagers with ADHD who had mutations in mGluR-network genes, over roughly five weeks.

Read that sample size again. Thirty teenagers, all pre-selected by a genetic test. This was a careful proof-of-concept, not proof that fasoracetam fixes ADHD broadly.

Why the Genetic Subgroup Is Everything

The genetic filter is the point, not a footnote. Even where fasoracetam may help ADHD in people with specific mGluR mutations, those cases represent around 10% of total ADHD, and the compound is likely ineffective for everyone else. Cognitive-improvement findings have come from that targeted context.

That is precision medicine logic. The drug aims to correct a specific glutamate-signaling fault, so it should only help people who actually carry that fault. If your ADHD has nothing to do with mGluR genes, there is no scientific reason to expect a response.

This is exactly why buying fasoracetam off a website to "treat focus" misreads the science.

Fasoracetam Dosage: What the Studies Used

Clinical fasoracetam dosage in the ADHD trials reached up to 400 mg twice daily, while nootropic users self-report far lower amounts with no clinical validation. The gap between those two numbers is a warning sign, not a guide.

In the controlled research, dosing was supervised and symptom-driven. One published trial administered fasoracetam at 100, 200, and 400 mg twice daily as part of a clinical protocol. A separate summary of children's ADHD research confirms doses of 100, 200, and 400 mg taken orally twice a day.

Hobbyist dosing looks nothing like that. Self-reported "starting" doses in the nootropic community fall around 10 to 20 mg per day, with anecdotal "effective" ranges scattered widely. None of those low-dose protocols come from peer-reviewed efficacy data.

Here is the honest read on dosing.

A wide self-experiment range with no controlled efficacy data is a reason for caution, not confidence.

Is Fasoracetam Legal and Safe to Buy?

Fasoracetam is not an approved drug and not a lawful dietary supplement ingredient, which puts it in a legal gray zone in the United States. This is the part most product pages bury.

The clearest summary comes from a nootropics retailer with no incentive to scare buyers. Fasoracetam is generally treated as a legal gray area: it is not a scheduled controlled substance, but it is also not FDA-approved and not a lawful dietary supplement ingredient to market for human consumption.

That status creates two real problems. First, products sold online are typically marketed as "research chemicals," with no manufacturing oversight you would expect from a medicine or a regulated supplement. Second, the long-term safety profile in healthy adults is simply not established, because the human data lives almost entirely in small, condition-specific trials.

None of this is medical advice. It is a description of where the compound actually stands.

Fasoracetam vs Studied Focus Ingredients

For day-to-day focus, fasoracetam is the wrong tool, because the human evidence applies to a narrow genetic group and the legal status blocks any quality-controlled product. If your goal is reliable everyday focus, ingredients with broader, repeatable evidence make far more sense.

Here is an honest comparison of fasoracetam against well-studied, legal focus ingredients, including the stack used by Roon.

The contrast is not subtle. One column is an unapproved trial compound for a rare genotype. The rest are studied ingredients you can actually use.

If you want to go deeper on those building blocks, our breakdowns of how caffeine and L-theanine work together and what makes Dynamine and TeaCrine different cover the everyday-focus side of this question.

A Genotype Drug Is Not a Focus Supplement

Fasoracetam is one of the more scientifically serious racetams, and that is exactly why its limits are so clear. It reached a real ADHD trial because researchers tied it to a specific glutamate-signaling defect, then tested it only in people who carried that defect.

The result was a promising proof-of-concept in about 30 adolescents with mGluR mutations, not a green light for general use. For the other 90% of ADHD cases, the science offers no reason to expect a benefit, and the legal status blocks any quality-controlled product anyway.

A precision drug aimed at a genotype is not a focus supplement. Treating it like one ignores the entire reason it was developed.

Frequently Asked Questions

Is fasoracetam approved for ADHD?

No. Fasoracetam is an investigational compound, not an approved ADHD medication. The main human evidence comes from a small trial in adolescents who carried specific mGluR gene mutations. Even there, the work was an early-stage proof-of-concept rather than a confirmation of broad effectiveness, and the compound has not cleared the regulatory path needed to be prescribed for ADHD.

How does fasoracetam differ from other racetams?

Most racetams act mainly on the AMPA receptor and cholinergic system. Fasoracetam instead targets metabotropic glutamate receptors, acting as a partial agonist at mGluR5 and influencing GABA-B receptors. That mechanism is why researchers paired it with a genetic test, selecting patients whose ADHD was linked to mGluR-network gene variants rather than treating ADHD as a single condition.

What dose of fasoracetam was used in studies?

The published ADHD trials used supervised doses of 100, 200, and 400 mg taken twice daily, with response guiding the increases. Those numbers came from a controlled clinical setting in a genetically selected group. Nootropic users self-report far lower amounts, often 10 to 50 mg per day, but none of those low-dose routines are backed by peer-reviewed efficacy data.

Is fasoracetam legal to buy?

In the United States, fasoracetam sits in a legal gray zone. It is not a scheduled controlled substance, but it is also not FDA-approved and not a lawful dietary supplement ingredient for human consumption. Products sold online are usually labeled "research chemicals," which means they lack the manufacturing oversight you would expect from a medicine or a regulated supplement.

Does fasoracetam work for everyone with ADHD?

Almost certainly not. The genetic mutations that the research targeted appear in roughly 10% of ADHD cases. For people without those mGluR-network variants, there is no clear scientific reason to expect a response. Fasoracetam was designed as a precision compound for a specific biology, not a general-purpose focus aid.

Is fasoracetam safe?

Its long-term safety in healthy adults is not established. Human data comes mostly from small, condition-specific trials, not from large studies in the general population. Combined with its unregulated sales status, that makes self-experimentation risky. Anyone considering it for a medical condition should talk to a qualified clinician rather than rely on forum protocols.

Where Studied Ingredients Beat an Unapproved Trial Compound

If you landed here hoping fasoracetam was a focus shortcut, the science gives a cleaner answer than the marketing does. Fasoracetam is an investigational drug for a genetically defined ADHD subgroup, not an over-the-counter performance aid, and you cannot buy a quality-controlled version of it legally.

That gap is the reason Roon is built the way it is. Instead of an unapproved trial compound, Roon uses a legal, studied stack in a sublingual pouch: 80 mg caffeine, 60 mg L-theanine, 25 mg methylliberine (Dynamine), and 5 mg theacrine (TeaCrine), designed for a 5 to 10 minute onset and 6 to 8 hours of focus with no jitters, no crash, and no tolerance buildup.

To be clear about what it is not: Roon is not a treatment for ADHD or any medical condition, and it is not a replacement for care from a clinician. It is a focus tool for everyday non-clinical demands. If you want sharper, steadier focus without wading into research-chemical territory, try Roon and judge it by how the rest of your day feels.

Written by Roon Team